Overview

Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects

Status:
Completed

Trial end date:
2006-12-01

Target enrollment:

Participant gender:

Summary

This is a randomised study of the effect of treatment with Combivir (zidovudine [AZT] and lamivudine [3TC]) and Kaletra (lopinavir [LPVr]), alone and in combination, on the development of abnormalities in lipid and glucose metabolism in HIV negative healthy subjects.

Phase:

Phase 4

Details

Lead Sponsor:

Kirby Institute

Collaborators:

Garvan Institute of Medical Research
National Heart, Lung, and Blood Institute (NHLBI)
Prince of Wales Hospital, Sydney
St Vincent's Hospital, Sydney

Treatments:

Lamivudine
Lamivudine, zidovudine drug combination
Lopinavir
Zidovudine